Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Condition | Approved For |
|---|---|---|---|---|---|---|---|
| AAB-003 | PF-05236812 | 1 | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | |
| Aducanumab | BIIB037 | 3 | Biogen | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | |
| BAN2401 | 2 | Biogen, Eisai Co., Ltd. | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | ||
| BMS-986168 | IPN007 | 1 | Bristol-Myers Squibb | Tau | Immunotherapy (passive) | Progressive Supranuclear Palsy | |
| Bapineuzumab | AAB-001 | Discontinued | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | |
| C2N 8E12 | ABBV-8E12 | 1, 2 | AbbVie, C2N Diagnostics, LLC | Tau | Immunotherapy (passive) | Progressive Supranuclear Palsy, Alzheimer's Disease | |
| Crenezumab | MABT5102A , RG7412 |
3 | AC Immune SA, Genentech, Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | None |
| Etanercept | Enbrel™ | 2 | Amgen, Inc., Pfizer | Inflammation | Immunotherapy (passive) | Alzheimer's Disease | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis |
| GSK933776 | Inactive | GlaxoSmithKline (GSK) | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | ||
| Gammagard® | Intravenous Immunoglobulin, IVIg |
Discontinued | Baxter Healthcare | Amyloid-Related, Inflammation | Immunotherapy (passive) | Alzheimer's Disease | Immunodeficiency conditions |
| Gamunex | Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma |
2/3 | Grifols Biologicals Inc. | Amyloid-Related, Inflammation | Immunotherapy (passive) | Alzheimer's Disease | Immunodeficiency, chronic inflammatory demyelinating neuropathy |
| Gantenerumab | RO4909832, RG1450 |
3 | Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | |
| LY2599666 | 1 | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | ||
| LY3002813 | N3pG-Aβ Monoclonal Antibody | 1 | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | |
| LY3303560 | 1 | Eli Lilly & Co. | Unknown | Immunotherapy (passive) | Alzheimer's Disease | ||
| MEDI1814 | 1 | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | ||
| Octagam®10% | Intravenous Immunoglobulin, NewGam |
Inactive, Inactive | Octapharma | Amyloid-Related, Inflammation | Immunotherapy (passive) | Alzheimer's Disease, Mild Cognitive Impairment | Immunodeficiency disorders |
| PRX002 | RG7935, NEOD002 | 1 | Prothena Corporation plc, Roche | alpha-synuclein | Immunotherapy (passive) | Parkinson's Disease | |
| Ponezumab | PF-04360365 | Discontinued, 2 | Pfizer | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease, Cerebral Amyloid Angiopathy | None |
| RG7345 | RO6926496 | Discontinued | Roche | Tau | Immunotherapy (passive) | Alzheimer's Disease | |
| RO 7105705 | RG 6100 | 1 | AC Immune SA, Genentech, Hoffmann-La Roche | Tau | Immunotherapy (passive) | Alzheimer's Disease | |
| SAR228810 | 1 | Sanofi | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | ||
| Solanezumab | LY2062430 | 3 | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | Alzheimer's Disease | None |